20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

Key Points

• Apella Capital increased its Bristol Myers Squibb stake by 159.2% in the third quarter, buying 20,370 shares to bring its holdings to 33,162 shares valued at approximately $2.07 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported positive Phase 3 results for its ZENBEXUS combination in relapsed or refractory multiple myeloma, potentially supporting an accelerated FDA approval and strengthening its oncology pipeline.
• Analysts’ consensus rating remains “Hold”, with an average price target of $64.96. BMY was trading at $59.18, while the company reported quarterly earnings and revenue above expectations and declared a $0.63 quarterly dividend.

Apella Capital LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 159.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,162 shares of the biopharmaceutical company's stock after purchasing an additional 20,370 shares during the period. Apella Capital LLC's holdings in Bristol Myers Squibb were worth $2,069,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BMY. Everhart Financial Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 2.2% during the 3rd quarter. Everhart Financial Group Inc. now owns 21,496 shares of the biopharmaceutical company's stock worth $1,341,000 after acquiring an additional 456 shares during the period. Avidian Wealth Enterprises LLC increased its stake in shares of Bristol Myers Squibb by 28.0% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 16,342 shares of the biopharmaceutical company's stock valued at $1,020,000 after purchasing an additional 3,576 shares during the last quarter. Valeo Financial Advisors LLC increased its stake in shares of Bristol Myers Squibb by 21.3% in the 3rd quarter. Valeo Financial Advisors LLC now owns 36,135 shares of the biopharmaceutical company's stock valued at $2,255,000 after purchasing an additional 6,351 shares during the last quarter. Vann Equity Management LLC acquired a new position in shares of Bristol Myers Squibb during the 3rd quarter worth $296,000. Finally, Steph & Co. lifted its position in shares of Bristol Myers Squibb by 5.5% during the 3rd quarter. Steph & Co. now owns 8,491 shares of the biopharmaceutical company's stock worth $530,000 after buying an additional 446 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported that its ZENBEXUS (iberdomide) combination achieved superior progression-free survival versus standard of care in the Phase 3 EXCALIBER-RRMM trial for relapsed or refractory multiple myeloma. The results also showed high minimal residual disease-negative complete response rates and could support an application for accelerated FDA approval, strengthening BMY’s oncology pipeline. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: J.P. Morgan reportedly assigned BMY a Buy rating, while recent commentary highlights the company’s oncology and hematology portfolio and its history of earnings surprises. These factors may support investor confidence in future growth and earnings. Bristol Myers Squibb Receives a Buy from J.P. Morgan

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMY. Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. Truist Financial reissued a "buy" rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Daiwa Securities Group upped their price objective on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley reissued an "underweight" rating and issued a $41.00 price objective (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $64.96.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Trading Down 0.7%

NYSE BMY opened at $59.18 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The business has a 50 day moving average price of $64.15 and a 200-day moving average price of $60.27. The company has a market cap of $120.89 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.29 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. During the same period last year, the business earned $1.46 EPS. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.91 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.